Key Highlights

  • Loss per share was USD 0.04, against an estimate of a USD 0.10 loss.
  • Net loss narrowed to USD 3.53 million from USD 8.18 million.
  • Research and development expenses fell to USD 1.56 million from USD 2.61 million.
  • Cash and cash equivalents were USD 11.71 million at September 30, 2026.

Galectin Therapeutics (NASDAQ:GALT) lost USD 3.53 million in the third quarter of 2026, against USD 8.18 million in the prior-year quarter. The basic and diluted net loss per common share was USD 0.04, against USD 0.13 and an estimated loss of USD 0.10. After preferred stock dividends of USD 37 thousand, the net loss applicable to common stockholders was USD 3.57 million.

Operating Expenses and Other Lines

Research and development expenses were USD 1.56 million, against USD 2.61 million, and general and administrative expenses were USD 1.80 million, against USD 1.59 million. Total operating expenses and the operating loss were USD 3.37 million, against USD 4.20 million.

Interest income was USD 28 thousand, against USD 39 thousand, and interest expense fell to USD 786 thousand from USD 1.82 million. The change in Fair Value of Derivatives was a gain of USD 594 thousand, against a loss of USD 2.21 million. Weighted average shares outstanding were 89,621 thousand, against 64,205 thousand.

The Nine-Month Picture

For the nine months ended September 30, 2026, the net loss was USD 17.69 million, against USD 25.34 million, and the net loss per common share was USD 0.24, against USD 0.40. Research and Development expenses were USD 5.93 million, against USD 12.36 million, and general and administrative expenses were USD 5.50 million, against USD 4.36 million. Total operating expenses were USD 11.43 million, against USD 16.72 million. Interest expense was USD 4.78 million, against USD 5.39 million, and the change in fair value of derivatives was a loss of USD 1.58 million, against a loss of USD 3.33 million.

Cash Runway and Going Concern

Cash and cash equivalents were USD 11.71 million at September 30, 2026, against USD 17.72 million at the prior Balance Sheet date, and total Assets were USD 13.01 million. The company believes it has enough cash, including availability under its line of credit, to fund currently planned operations through June 2027.

The filing also says the factors it describes raise substantial doubt about the company's ability to continue as a Going Concern for 12 months from the date the financial statements are issued, and that its cash may not be enough to support daily operations after June 2027.

Total current assets were USD 12.91 million, against USD 19.44 million, and prepaid expenses and other current assets were USD 1.20 million, against USD 1.72 million. The filing notes that on December 20, 2021 the second of two promissory notes under the company's Loan agreement was executed, evidencing a second loan with a principal amount of USD 10.0 million.

The Quarter in Brief

Galectin Therapeutics reported a third quarter 2026 net loss of USD 3.53 million and a loss of USD 0.04 per share. Cash and cash equivalents were USD 11.71 million at September 30, 2026.